We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Read MoreHide Full Article
Positive news flowed in at Celgene Corporation when the European Commission approved a label expansion of Revlimid. With the label expansion, Revlimid can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).
EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion earlier this year. The approval was based on positive data from a phase II study (MCL-002) which evaluated the efficacy and safety of Revlimid versus the investigator's choice in patients who were refractory to their last treatment or had relapsed one to three times. Revlimid significantly improved progression-free survival of 8.7 months versus 5.2 months in the control arm.
Revlimid is expected to provide a new treatment option to patients living in the EU with relapsed/refractory MCL. Per the company’s press release, MCL is a rare sub-type of aggressive non-Hodgkin's lymphoma (NHL) with 3–6% of NHL patients suffering from MCL. MCL has the poorest long-term survival of all B-cell lymphoma subtypes with fewer than 50% of patients surviving at 5 years.
We are encouraged by the label expansion of Revlimid. Revlimid is the key growth driver at Celgene. In 2015, Revlimid recorded global sales of $5.8 billion, reflecting an increase of 16.5%. Label expansion should boost the drug’s sales further.
We note that Revlimid is already approved in the U.S. for the treatment of patients with relapsed/refractory MCL. It is also approved in several countries including the EU for the treatment of newly diagnosed and relapsed/refractory multiple myeloma and myelodysplastic syndromes. Meanwhile, Celgene is working on expanding Revlimid’s label further.
Celgene is currently a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Fibrocell Science, Inc. , Innoviva, Inc. (INVA - Free Report) and Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . All three stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Positive news flowed in at Celgene Corporation when the European Commission approved a label expansion of Revlimid. With the label expansion, Revlimid can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).
EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion earlier this year. The approval was based on positive data from a phase II study (MCL-002) which evaluated the efficacy and safety of Revlimid versus the investigator's choice in patients who were refractory to their last treatment or had relapsed one to three times. Revlimid significantly improved progression-free survival of 8.7 months versus 5.2 months in the control arm.
Revlimid is expected to provide a new treatment option to patients living in the EU with relapsed/refractory MCL. Per the company’s press release, MCL is a rare sub-type of aggressive non-Hodgkin's lymphoma (NHL) with 3–6% of NHL patients suffering from MCL. MCL has the poorest long-term survival of all B-cell lymphoma subtypes with fewer than 50% of patients surviving at 5 years.
CELGENE CORP Price
CELGENE CORP Price | CELGENE CORP Quote
We are encouraged by the label expansion of Revlimid. Revlimid is the key growth driver at Celgene. In 2015, Revlimid recorded global sales of $5.8 billion, reflecting an increase of 16.5%. Label expansion should boost the drug’s sales further.
We note that Revlimid is already approved in the U.S. for the treatment of patients with relapsed/refractory MCL. It is also approved in several countries including the EU for the treatment of newly diagnosed and relapsed/refractory multiple myeloma and myelodysplastic syndromes. Meanwhile, Celgene is working on expanding Revlimid’s label further.
Celgene is currently a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Fibrocell Science, Inc. , Innoviva, Inc. (INVA - Free Report) and Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . All three stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>